ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,680 GBX | +1.04% |
|
+2.79% | +19.66% |
| 10:03am | AstraZeneca: Tagrisso approved in China for NSCLC | CF |
| 09:42am | AstraZeneca's Tagrisso plus chemo gets approval in China | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.66% | 247B | |
| +55.19% | 815B | |
| +45.62% | 654B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +3.56% | 229B | |
| +13.99% | 219B | |
| +10.86% | 171B | |
| -2.78% | 159B | |
| +1.83% | 122B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Astrazeneca Says Imfinzi Approved In U.S. For Endometrial Cancer
